Indeed, Cntnap2 is expressed in the MGE progenitors cells in humans (Satterstrom et al., 2020), and in future sub-pallial cholinergic and GABAergic neurons (Shi et al., 2021), suggesting that potential therapeutic interventions could be conducted from embryonic stages to rectify the altered developmental trajectory in ASD, but also a range of neurodevelopmental disorders such as schizophrenia, intellectual disability, dyslexia, epilepsy and attention-deficit hyperactivity disorder (Rodenas-Cuadrado et al., 2014; Poot, 2015). Here, CNTNAP2 is linked to schizophrenia.